| Literature DB >> 27816064 |
Marie Morimoto1,2, Clara Myung1,2, Kimberly Beirnes1,2, Kunho Choi1,2, Yumi Asakura3, Arend Bokenkamp4, Dominique Bonneau5, Milena Brugnara6, Joel Charrow7, Estelle Colin5, Amira Davis8, Georges Deschenes9, Mattia Gentile10, Mario Giordano11, Andrew K Gormley12, Rajeshree Govender13, Mark Joseph14, Kory Keller15, Evelyne Lerut16, Elena Levtchenko17, Laura Massella18, Christy Mayfield19, Behzad Najafian20, David Parham21, Jurgen Spranger22, Peter Stenzel23, Uluc Yis24, Zhongxin Yu25, Jonathan Zonana15, Glenda Hendson26, Cornelius F Boerkoel27,28,29.
Abstract
BACKGROUND: Schimke immuno-osseous dysplasia (SIOD) is a multisystemic disorder caused by biallelic mutations in the SWI/SNF-related matrix-associated actin-dependent regulator of chromatin, subfamily A-like 1 (SMARCAL1) gene. Changes in gene expression underlie the arteriosclerosis and T-cell immunodeficiency of SIOD; therefore, we hypothesized that SMARCAL1 deficiency causes the focal segmental glomerulosclerosis (FSGS) of SIOD by altering renal gene expression. We tested this hypothesis by gene expression analysis of an SIOD patient kidney and verified these findings through immunofluorescent analysis in additional SIOD patients and a genetic interaction analysis in Drosophila.Entities:
Keywords: Focal segmental glomerulosclerosis; Notch signaling pathway; SMARCAL1 protein; Schimke immuno-osseous dysplasia; Wnt signaling pathway
Mesh:
Substances:
Year: 2016 PMID: 27816064 PMCID: PMC5097426 DOI: 10.1186/s13023-016-0519-7
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
The renal parameters of the SIOD patients included in this study
| Patient ID | Age at onset (years) | Age at death (years) | Nephrotic syndrome | Hypertension | Proteinuria | Hypercholesterolemia | Renal dialysis | Age at renal dialysis (years) | Renal transplant | Age at renal transplantation (years) | Renal pathology |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SD4b | 3 | 8 | + | + | + | ? | − | n/a | − | n/a | FSGS |
| SD26 | <4 | 8 | + | + | + | + | + | 5 | − | n/a | FSGS |
| SD60 | 7 | 13.7 | + | + | + | ? | + | 12.5 | + | 13 | FSGS |
| SD79 | <4 | 10 | + | − | + | − | − | n/a | − | n/a | FSGS |
| SD120 | 4.5 | 5.4 | + | + | + | + | − | n/a | − | n/a | FSGS |
| SD121 | 2.5 | 4.8 | + | − | + | + | − | n/a | − | n/a | Diffuse podocytopathy with early features of FSGS |
| SD131 | 3 | 4.6 | + | + | + | + | + | 3.8 | − | n/a | Global glomerulosclerosis likely secondary to FSGS |
| SD146 | 2 | 4 | − | − | + | + | − | n/a | − | n/a | FSGS |
Abbreviations: + present, − absent, ? unknown, FSGS focal segmental glomerulosclerosis, ID identification, n/a not applicable, SIOD Schimke immuno-osseous dysplasia
Fig. 1Genome-wide and targeted gene expression analyses in an SIOD patient kidney. a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of upregulated genes (log2 fold change > 1) in an SIOD kidney compared to a sex-matched unaffected control kidney. A Bonferroni-corrected p value of < 0.05 was used as a threshold for determining significant KEGG pathways. The horizontal axis represents the -log10 (p value) of significant KEGG pathways. The number of unique DAVID gene IDs involved in a given term is indicated within the bar representing each pathway. b and c Volcano plots comparing the expression of Wnt (b) and Notch (c) pathway genes and targets in an SIOD patient kidney to an unaffected control kidney. White, grey, and black dots respectively represent downregulated (log2 fold change < −1), unchanged, and upregulated (log2 fold change > 1) expression in the SIOD kidney versus the unaffected control kidney. For genes above the dotted line, the differential expression has a p value of less than 0.05. Abbreviations: ECM, extracellular matrix; SIOD, Schimke immuno-osseous dysplasia
Fig. 3Immunofluorescent detection of the Notch1 intracellular domain (NICD) in the glomerular cells of SIOD patient and unaffected control kidneys. Immunostaining with anti-NICD (Alexa Fluor 594) in positive control skin (a), unaffected control kidney (b), and SIOD patient kidneys (c-j). The nuclei were counterstained with 4', 6-diamidino-2-phenylindole (DAPI). The boxed regions on the left correspond to the higher magnification images on the right. Scale bars: overview images (400×) = 100 microns; higher magnification images (1000×) = 10 microns. Abbreviations: DAPI, 4', 6-diamidino-2-phenylindole; NICD, Notch1 intracellular domain
Fig. 2Immunofluorescent detection of unphosphorylated β-catenin in the glomerular cells of SIOD patient and unaffected control kidneys. Immunostaining with anti-unphosphorylated β-catenin (Alexa Fluor 594) in unaffected control kidney (a) and SIOD patient kidneys (b-h). The nuclei were counterstained with 4', 6-diamidino-2-phenylindole (DAPI). The boxed regions correspond to the higher magnification images on the right. The glomeruli have been outlined to aid in the visualization of β-catenin expression. Scale bars: overview images (200×) and higher magnification images (400×) = 100 microns. Abbreviations: DAPI, 4', 6-diamidino-2-phenylindole
Summary of the β-catenin and NICD immunofluorescent analyses in SIOD and isolated FSGS patient kidney tissue
| Patient ID | Unphosphorylated β-catenin expression | Nuclear NICD expression |
|---|---|---|
| SIOD patients | ||
| SD4b | = | = |
| SD26 |
|
|
| SD60 |
|
|
| SD60 Tx | = | = |
| SD79 |
| = |
| SD120 |
|
|
| SD121 |
|
|
| SD131 | n/aa |
|
| SD146 |
|
|
| Isolated FSGS patients | ||
| FSGS-1 |
| = |
| FSGS-2 |
|
|
| FSGS-3 |
|
|
| FSGS-4 |
|
|
| FSGS-5 |
|
|
| FSGS-6 |
|
|
| FSGS-8 |
|
|
| FSGS-9 |
|
|
| FSGS-10 |
|
|
Abbreviation: = staining comparable to unaffected control kidney, increased staining compared to unaffected control kidney, FSGS focal segmental glomerulosclerosis, ID identification, n/a not available, NICD Notch1 intracellular domain, SIOD Schimke immuno-osseous dysplasia, Tx transplant
aNo more tissue sections were available for analysis
Fig. 4Genetic interaction of Marcal1 loss and gain with Notch pathway mutant alleles and model. a Representative wings of the mutant allele of interest (left column), the mutant allele in the Marcal1 loss-of-function background (middle column), and the mutant allele in the Marcal1 overexpression background (right column). Hairless (H), Delta (Dl), and Serrate (Ser) are dominant alleles on chromosome 3. Although both heterozygous males and females were assessed, representative wings from females are shown. The N allele is a homozygous viable allele of Notch on chromosome 1. Although both homozygous females and hemizygous males were assessed, representative wings from hemizygous males are shown. b Representative eyes of the mutant allele N (left), the mutant allele in the Marcal1 loss-of-function background (middle), and the mutant allele in the Marcal1 overexpression background (right). The N allele is a homozygous viable allele of Notch on chromosome 1. Although both homozygous females and hemizygous males were assessed, representative eyes from hemizygous males are shown. c Model of renal disease pathogenesis in SIOD. Normal SMARCAL1 activity leads to regulated signaling of pathways and normal kidney development and function, whereas loss of SMARCAL1 activity leads to dysregulated Wnt and/or Notch signaling and in turn causes FSGS